Real-world evidence on data quality in precision oncology platforms: insights from the Molecular Twin Research Umbrella protocol - Top-Institutions - MDSpire

Real-world evidence on data quality in precision oncology platforms: insights from the Molecular Twin Research Umbrella protocol

  • By

  • Michael Zuniga

  • Denis Marino

  • Yuan Yuan

  • Jin Sun Lee

  • Nazelee Dagliyan

  • Dominique Pope

  • Gangothri Namasivayam

  • Hui Hong

  • Grant Dagliyan

  • Warren G. Tourtellotte

  • Robert Figlin

  • Karine Sargsyan

  • June 30, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, NY

    Key Differentiators

    • Oncology

  • #2

    Cedars-Sinai Medical Center
    Cedars-Sinai Medical Center

    Los Angeles, CA

    Key Differentiators

    • Oncology

  • #3

    National Cancer Institute
    National Cancer Institute

    Bethesda, MD

    Key Differentiators

    • Oncology

  • #4

    Massachusetts General Hospital
    Massachusetts General Hospital

    Boston, MA

    Key Differentiators

    • Oncology

  • #5

    Center for Molecular Oncology
    Center for Molecular Oncology

    New York, NY

    Key Differentiators

    • Oncology

Original Source(s)

Real-world evidence on data quality in precision oncology platforms: insights from the Molecular Twin Research Umbrella protocol

  • by Michael Zuniga, Denis Marino, Yuan Yuan, Jin Sun Lee, Nazelee Dagliyan, Dominique Pope, Gangothri Namasivayam, Hui Hong, Grant Dagliyan, Warren G. Tourtellotte, Robert Figlin, Karine Sargsyan

  • June 30, 2026

Related Content

Metabolic sovereignty through oxidative hostility: a mechanistic perspective on how cancer engineers stromal dependency via ROS-mediated lysosomal reprogramming

Mapping the evolving landscape of artificial intelligence in pathology: A bibliometric analysis of research trends and emerging frontiers (2009-2025)

High FCRL5 expression predicts poor treatment response and survival in newly diagnosed multiple myeloma: a retrospective study